Brought to you by 
Takeda licenses microbiome IBD candidate from Finch Therapeutics; terminates partnership
26 Aug 2022
Executive Summary
Finch Therapeutics Inc. granted Takeda Pharmaceutical Co. Ltd. exclusive global rights to develop and sell its microbiome candidate FIN524, which is in preclinical studies for inflammatory bowel disease.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Takeda licenses microbiome IBD candidate from Finch Therapeutics; terminates partnership
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice